Bard Financial Services’s Alexion Pharmaceuticals ALXN Stock Holding History

Bard Financial Services’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,175	Closed	-$216K	–	285
2021 Q2	$216K	Buy	+1,175	New	+$202K	0.02%	253
2021 Q1	–	Sell	-1,600	Closed	-$250K	–	269
2020 Q4	$250K	Buy	+1,600	New	+$206K	0.03%	222

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Bard Financial Services's ALXN Position: Q3 2021 in Review

Bard Financial Services sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,175 shares — an estimated $216K sold.

Bard Financial Services first reported a position in ALXN in Q4 2020 and held it in 2 quarters. The position peaked at $250K in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Bard Financial Services reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Bard Financial Services sold 1,175 Alexion Pharmaceuticals shares in Q3 2021, an estimated $216K.
Bard Financial Services first reported a position in Alexion Pharmaceuticals in Q4 2020 and held it in 2 quarters.
Bard Financial Services's Alexion Pharmaceuticals position peaked at $250K in Q4 2020.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Bard Financial Services's 13F filing for Q3 2021, filed 15 Oct 2021.